Form 4: Avadel Pharmaceuticals Acquired by Alkermes

Avadel Pharmaceuticals plc director Peter J. Thornton reports the disposition of all shares and options following the company's acquisition by Alkermes plc for $21.00 cash plus a contingent value right per share.

Summary

• Avadel Pharmaceuticals plc was acquired by Alkermes plc through a scheme of arrangement, effective February 12, 2026.
• The acquisition was conducted under a Transaction Agreement dated October 22, 2025, which was amended on November 18, 2025.
• At the effective time, each outstanding Ordinary Share of Avadel was converted into $21.00 in cash and one non-transferable contingent value right (CVR).
• Each CVR provides holders with a potential additional cash payment of $1.50 per share, contingent upon the achievement of specific milestones.
• All Restricted Stock Awards vested fully at the effective time and were treated in the same manner as Ordinary Shares.
• Outstanding stock options were canceled and exchanged for cash (calculated as the total number of shares subject to the option multiplied by the excess of the Cash Consideration over the option's exercise price) and one CVR per share subject to the option.
• Director Peter J. Thornton disposed of 115,060 Ordinary Shares and 241,000 shares underlying various stock options, resulting in zero beneficial ownership of Avadel securities.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive event for Avadel shareholders, as it represents a successful exit with a significant cash component and potential additional upside through CVRs, indicating a favorable valuation for the company.

Positives

• Shareholders received a substantial cash consideration of $21.00 per Ordinary Share as part of the acquisition.
• The inclusion of Contingent Value Rights (CVRs) offers shareholders the potential for an additional $1.50 per share upon the achievement of certain milestones.
• All Restricted Stock Awards vested in full, allowing holders to realize value from their equity awards under the acquisition terms.
• Stock options, regardless of their vesting status, were cashed out and also received CVRs, providing value to option holders.

Negatives

• Avadel Pharmaceuticals plc has ceased to be an independent publicly traded company following its acquisition by Alkermes plc.
• Former shareholders no longer hold direct equity in Avadel Pharmaceuticals plc.
• The additional $1.50 per share from the Contingent Value Rights (CVRs) is not guaranteed and is dependent on future milestone achievements.

Risks

• The contingent value right (CVR) payment of $1.50 per share is not guaranteed and is dependent on the achievement of certain unspecified milestones.

Future Outlook

The future outlook for former Avadel shareholders includes the potential to receive an additional $1.50 per share through Contingent Value Rights (CVRs), which are contingent upon the achievement of specific, undisclosed milestones.

Industry Context

StockSavvy.ai notes that the acquisition of Avadel Pharmaceuticals by Alkermes plc represents a consolidation within the pharmaceutical sector, a common trend where larger companies acquire smaller, specialized firms to expand their product pipelines or market share. This particular transaction, involving a cash component and CVRs, is a frequently used structure in biotech and pharma M&A, allowing buyers to mitigate risk associated with pipeline assets while offering sellers potential upside.

Comparison to Industry Standards

• StockSavvy.ai observes that the deal structure, combining an upfront cash payment ($21.00 per share) with a contingent value right (CVR) for an additional $1.50 per share, aligns with common practices in pharmaceutical and biotechnology acquisitions. For instance, similar CVR structures have been seen in deals like Bristol Myers Squibb's acquisition of Celgene, where CVRs were tied to regulatory approvals of specific drugs.
• The total potential value of $22.50 per share (cash + CVR) would need to be compared against Avadel's pre-announcement trading price and analyst price targets to assess the premium offered. Without this context, a direct comparison to specific comparable companies' acquisition premiums (e.g., recent acquisitions in the sleep disorder or CNS therapeutic areas) is not fully possible from this filing alone. However, the inclusion of a CVR suggests that there was a valuation gap or a desire to share future development risks/rewards, a strategy employed in deals such as Sanofi's acquisition of Synthorx.

Stakeholder Impact

• Shareholders: Received cash consideration and CVRs, representing a liquidity event and potential upside. They no longer hold equity in Avadel.
• Employees: While not explicitly stated, acquisitions often lead to integration and potential restructuring, which could impact employees.
• Management: The reporting person, a director, disposed of all holdings, indicating a change in their direct involvement with the acquired entity.

Next Steps

• Achievement of milestones for the Contingent Value Rights (CVRs) to trigger the additional $1.50 per share payment.

Key Dates

Keywords

Avadel Pharmaceuticals, Alkermes, acquisition, merger, SEC Form 4, beneficial ownership, contingent value right, CVR, scheme of arrangement, stock options, restricted stock awards